Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Adenine/analogs & derivatives/administration & dosage (1)
- Administration (1)
- Alanine (1)
- Animal (1)
- Animals (1)
-
- Anti-HIV agents/adminstration & dosage (1)
- Antibody stabilization (1)
- Broadly neutralizing antibodies (1)
- Cervicovaginal (1)
- Copper intrauterine device (1)
- Depot medroxyprogesterone acetate (1)
- Disease models (1)
- Elvitegravir (1)
- Estronogestrel (1)
- HIV (1)
- HIV pre-exposure and postexposure prophylaxis (1)
- HIV prevention in infants (1)
- HSV-2 (1)
- Levonorgestrel (1)
- Macaca (1)
- Macaca mulatta (1)
- Macaque models (1)
- Male (1)
- Microarray patch (1)
- Microneedles (1)
- Oestrogen (1)
- Post-exposure prophylaxis/methods (1)
- Quinolones/administration & dosage/therapeutic use (1)
- Rectal (1)
- Rectum/virology (1)
Articles 1 - 3 of 3
Full-Text Articles in Equipment and Supplies
Proof-Of-Concept Development And Preclinical Evaluation Of A Microarray Patch Platform For Codelivery Of Multiple Broadly Neutralizing Antibodies For Hiv Prevention, M. Melissa Peet, Vivek Agrahari, Parbeen Singh, Lam Luong Hoai Nguyen, Louise A. Ouattara, Eun Sung Yang, Carolina Herrera, Amarendra Pegu, Theodore C. Pierson, Thanh D. Nguyen, Gustavo F. Doncel
Proof-Of-Concept Development And Preclinical Evaluation Of A Microarray Patch Platform For Codelivery Of Multiple Broadly Neutralizing Antibodies For Hiv Prevention, M. Melissa Peet, Vivek Agrahari, Parbeen Singh, Lam Luong Hoai Nguyen, Louise A. Ouattara, Eun Sung Yang, Carolina Herrera, Amarendra Pegu, Theodore C. Pierson, Thanh D. Nguyen, Gustavo F. Doncel
CONRAD Publications
Broadly neutralizing antibodies (bnAbs) are advancing as a preventative or treatment option for HIV infection, but currently must be administered parenterally, typically as a large injection or infusion, an invasive method of delivery, especially for the pediatric population. Here, we present proof-of-concept data on a minimally invasive microneedle (MN) patch platform codelivering three bnAbs, PGT121, VRC07-523LS, and PGDM1400LS, from separate MN patch units or pixels. Each 1 cm² patch pixel, fabricated via solvent casting, contained similar to 2 mg of one bnAb. In ex vivo porcine skin tests, the MNs effectively penetrated the skin. When tested in vitro in PBS …
Partial Post-Exposure Protection By Topical Inserts Containing Tenofovir Alafenamide Fumarate/Elvitegravir In A Macaque Model Of Rectal Simian Hiv (Shiv) Infection, Natalia Makarova, Tyana Singletary, M. Melissa Peet, Kristen Kelley, Ryan Johnson, Vivek Agrahari, Maria Mendoza, Yi Pan, Walid Heneine, Meredith R. Clark, J. Gerardo García Lerma, Gustavo F. Doncel, James W. Smith
Partial Post-Exposure Protection By Topical Inserts Containing Tenofovir Alafenamide Fumarate/Elvitegravir In A Macaque Model Of Rectal Simian Hiv (Shiv) Infection, Natalia Makarova, Tyana Singletary, M. Melissa Peet, Kristen Kelley, Ryan Johnson, Vivek Agrahari, Maria Mendoza, Yi Pan, Walid Heneine, Meredith R. Clark, J. Gerardo García Lerma, Gustavo F. Doncel, James W. Smith
CONRAD Publications
On-demand topical inserts for HIV prevention may be a good option for people who have a low frequency of sexual activity. We recently demonstrated in a preclinical macaque model that rectal application of inserts containing tenofovir alafenamide fumarate (TAF) and elvitegravir (EVG) conferred protection against SHIV infection (93% efficacy) when applied as pre-exposure prophylaxis 4 hours before SHIV exposure. Here, we show that the same inserts provide significant postexposure protection (82.9% efficacy) when applied 4 hours after SHIV exposure. Our findings further support the ongoing clinical development of TAF/EVG inserts for on-demand HIV prevention.
Impact Of Contraceptive Initiation On The Cervicovaginal Mucosa: Results From The Umpala Multicentre Partially Randomized Patient-Preference Interventional Trial, Betty Njoroge, Nelly Mugo, Carolina Herrera, Karen Dominguez, Louise A. Ouattara, Nazita Yousefieh, Neelima Chandra, Agnieszka Kurczewska, Stephanie Nartey, Julie Lewis, Andrea R. Thurman, Matilda Saina, Raina N. Fichorova, Jacques Ravel, Reem Sharaf Alddin, Nicola Richardson-Harman, Kenneth Ngure, Gustavo F. Doncel
Impact Of Contraceptive Initiation On The Cervicovaginal Mucosa: Results From The Umpala Multicentre Partially Randomized Patient-Preference Interventional Trial, Betty Njoroge, Nelly Mugo, Carolina Herrera, Karen Dominguez, Louise A. Ouattara, Nazita Yousefieh, Neelima Chandra, Agnieszka Kurczewska, Stephanie Nartey, Julie Lewis, Andrea R. Thurman, Matilda Saina, Raina N. Fichorova, Jacques Ravel, Reem Sharaf Alddin, Nicola Richardson-Harman, Kenneth Ngure, Gustavo F. Doncel
CONRAD Publications
Background: Long-acting contraceptives are widely used, providing superior efficacy and systemic safety; however, the impact of contraceptive initiation on female genital tract function and health has been understudied.
Methods: Non-pregnant, HIV-uninfected women aged 18–50 years were enrolled in a dual-centre partially randomized patient-preference interventional trial (NCT04814927) and allowed to choose one of four contraceptive options, etonogestrel contraceptive implant, depot medroxyprogesterone acetate subcutaneous injection, levonorgestrel intrauterine device, and copper IUD, with a minimum target of 12 participants per arm and site. Sampling took place at baseline, 1 and 3 months after contraceptive initiation, and 1 month post-contraceptive discontinuation. Primary outcomes focused …